Transgene SA 2018 IR
The report highlights Transgene's strategic and financial progress in 2018, focusing on its clinical-stage immunotherapies and novel technology platforms, myvac™ and Invir.IO™. Key achievements include the sale of Chinese rights for TG1050 and TG6002 to Tasly BioPharmaceuticals for $48 million and the advancement of clinical trials for TG4010, Pexa-Vec, and TG4001. In terms of sustainability, the company maintained its commitment to social responsibility, gender equality, and workplace safety, reporting a low absenteeism rate of 2.21% and zero occupational illnesses. Environmental efforts focused on reducing energy consumption, with electricity usage at 3,346,907 kWh for the year.
Company: Transgene SA
Sector: Professional & technical services
Country: France
Year: 2018
Type: IR
Pages: 204
Back to company
Transgene SA
Registration Document
The report highlights Transgene's strategic and financial progress in 2018, focusing on its clinical-stage immunotherapies and novel technology platforms, myvac™ and Invir.IO™. Key achievements include the sale of Chinese rights for TG1050 and TG6002 to Tasly BioPharmaceuticals for $48 million and the advancement of clinical trials for TG4010, Pexa-Vec, and TG4001. In terms of sustainability, the company maintained its commitment to social responsibility, gender equality, and workplace safety, reporting a low absenteeism rate of 2.21% and zero occupational illnesses. Environmental efforts focused on reducing energy consumption, with electricity usage at 3,346,907 kWh for the year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2018
Reporting Period
Jan 1, 2018 - Dec 31, 2018
Fiscal Year
2018
Published
Apr 3, 2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Employees